Form 4: Processa Pharmaceuticals Executive Sian Bigora Reports Stock Transactions

Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, reports multiple transactions involving common stock and restricted stock units.

Summary

• Sian Bigora, the Chief Development Officer of Processa Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On April 5, 2024, Bigora acquired 1,675 shares of common stock through the distribution of vested restricted shares and disposed of 368 shares at a price of $2.79.
• On July 10, 2024, Bigora acquired 644 shares of common stock through the distribution of vested restricted shares and disposed of 225 shares at a price of $1.71.
• Bigora also holds 6,668 shares indirectly through CorLyst, LLC.
• Bigora was granted multiple tranches of Restricted Stock Units (RSUs) that convert to common stock, vesting at various dates in the future.
• Following these transactions, Bigora directly owns 21,878 shares of common stock and holds rights to 27,961 shares through Restricted Stock Units.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing. The transactions themselves don't necessarily indicate positive or negative sentiment, but rather provide a snapshot of insider activity.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may be interested in the insider's transactions as an indicator of management's confidence in the company.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Processa Pharmaceuticals, Insider Trading, Sian Bigora, PCSA